Mark C Gillies1, Richard Walton, Julines Liong, Jennifer J Arnold, Ian McAllister, Nigel Morlet, Alex Hunyor, Robyn Guymer, Jill Keeffe, Rohan Essex, Amparo Herrera-Bond, Briony Glastonbury, Judy M Simpson, Daniel Barthelmes. 1. *Save Sight Institute, Sydney Medical School, University of Sydney, Sydney, Australia; †Information and Communications Technology, University of Sydney, Sydney, Australia; ‡Marsden Eye Specialists, Parramatta, New South Wales, Australia; §Lions Eye Institute, Center for Ophthalmology and Vision Science and ¶Department of Population Health, University of Western Australia, Perth, Australia; **Retina Associates, Chatswood, Sydney, Australia; ††Department of Ophthalmology, Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Australia; ‡‡Department of Ophthalmology, Canberra Hospital, Canberra, Australia; §§Sydney School of Public Health, University of Sydney, Sydney, Australia; and ¶¶Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland.
Abstract
PURPOSE: To describe the development of a web-based high-quality data collection tool to track the outcomes of treatment of macular disease in routine practice. METHODS: Testing of a larger data collection tool established which fields a clinician would reliably fill out. The program, which was developed using freely available software, consists of modules interacting with a core system. The module for neovascular age-related macular degeneration is described here. RESULTS: Data for initial visits can be entered within 30 seconds, 15 seconds for follow-up visits. Fifteen centers from Australia, New Zealand, and Switzerland are currently contributing data. Finalized data from 2,052 eyes of 1,693 participants dating from January 2006 were analyzed. Median (25th and 75th percentiles) visual acuity at the index visit was 55 (41, 68) logarithm of the minimum angle of resolution letters with the following lesion types: minimally classic 17.2%, predominantly classic 24.6%, occult 52.0%, idiopathic polypoidal choroidal vasculopathy 1.2%, and retinal angiomatous proliferation 3.2%. CONCLUSION: This software tool will facilitate the collection of large amounts of data on the routine use of treatments of neovascular age-related macular degeneration. This will allow us to analyze important potentially modifiable variables, such as the effect of different treatment patterns on visual outcomes, and to evaluate new treatments as they are introduced into practice.
PURPOSE: To describe the development of a web-based high-quality data collection tool to track the outcomes of treatment of macular disease in routine practice. METHODS: Testing of a larger data collection tool established which fields a clinician would reliably fill out. The program, which was developed using freely available software, consists of modules interacting with a core system. The module for neovascular age-related macular degeneration is described here. RESULTS: Data for initial visits can be entered within 30 seconds, 15 seconds for follow-up visits. Fifteen centers from Australia, New Zealand, and Switzerland are currently contributing data. Finalized data from 2,052 eyes of 1,693 participants dating from January 2006 were analyzed. Median (25th and 75th percentiles) visual acuity at the index visit was 55 (41, 68) logarithm of the minimum angle of resolution letters with the following lesion types: minimally classic 17.2%, predominantly classic 24.6%, occult 52.0%, idiopathic polypoidal choroidal vasculopathy 1.2%, and retinal angiomatous proliferation 3.2%. CONCLUSION: This software tool will facilitate the collection of large amounts of data on the routine use of treatments of neovascular age-related macular degeneration. This will allow us to analyze important potentially modifiable variables, such as the effect of different treatment patterns on visual outcomes, and to evaluate new treatments as they are introduced into practice.
Authors: Maria Oliva Grassi; Claudio Furino; Nicola Recchimurzo; Fabio De Vitis; Giancarlo Sborgia; Luigi Sborgia; Arianna Meleleo; Teresa Molfetta; Marina Piepoli; Paolo Locatelli; Francesco Boscia; Giovanni Alessio Journal: Int Ophthalmol Date: 2020-06-08 Impact factor: 2.031
Authors: Daniel Barthelmes; Vuong Nguyen; Richard Walton; Mark C Gillies; Vincent Daien Journal: Graefes Arch Clin Exp Ophthalmol Date: 2018-07-27 Impact factor: 3.117
Authors: Tiarnan D Keenan; Susan Vitale; Elvira Agrón; Amitha Domalpally; Andrew N Antoszyk; Michael J Elman; Traci E Clemons; Emily Y Chew Journal: Ophthalmol Retina Date: 2019-06-11
Authors: Juan Lyn Ang; Sarah Ah-Moye; Leah N Kim; Vuong Nguyen; Adrian Hunt; Daniel Barthelmes; Mark C Gillies; Hemal Mehta Journal: Eye (Lond) Date: 2020-04-20 Impact factor: 3.775
Authors: Vuong Nguyen; Martin Puzo; Jorge Sanchez-Monroy; Pierre-Henry Gabrielle; Catherine C Garcher; Florian Baudin; Benjamin Wolff; Laurent Castelnovo; Guillaume Michel; Louise O'Toole; Daniel Barthelmes; Mark C Gillies Journal: Retina Date: 2021-07-01 Impact factor: 4.256
Authors: Daniel Barthelmes; Anna Campain; Phuc Nguyen; Jennifer J Arnold; Ian L McAllister; Judy M Simpson; Alex P Hunyor; Robyn Guymer; Rohan W Essex; Nigel Morlet; Mark C Gillies Journal: Br J Ophthalmol Date: 2016-03-18 Impact factor: 4.638